Sanofi (SNY) to Release Earnings on Thursday

Sanofi (NASDAQ:SNY) is expected to be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Sanofi to post earnings of $1.09 per share and revenue of $12.4453 billion for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Sanofi Price Performance

SNY stock opened at $43.79 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The firm has a 50-day moving average of $43.42 and a 200 day moving average of $45.40. The company has a market cap of $106.17 billion, a P/E ratio of 12.23, a PEG ratio of 1.11 and a beta of 0.34.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the third quarter valued at approximately $29,000. Palisade Asset Management LLC bought a new position in Sanofi in the 3rd quarter valued at approximately $30,000. Sittner & Nelson LLC purchased a new stake in Sanofi during the 3rd quarter valued at $47,000. WealthCollab LLC boosted its stake in Sanofi by 21.6% during the 3rd quarter. WealthCollab LLC now owns 1,538 shares of the company’s stock valued at $73,000 after purchasing an additional 273 shares during the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Sanofi by 618.7% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,271 shares of the company’s stock worth $107,000 after purchasing an additional 1,955 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Morgan Stanley set a $49.00 price target on Sanofi in a research note on Wednesday, July 8th. Argus raised Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Finally, BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $49.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.